PMEF
FDMT icon

Point72 Middle East FZE’s 4D Molecular Therapeutics FDMT Stock Holding History

Point72 Middle East FZE’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,304
Closed -$144K – 1614
2023
Q3 		$144K Buy
+11,304
New +$189K ﹤0.01% 1077

Other funds holding FDMT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Point72 Middle East FZE's FDMT Position: Q4 2023 in Review

Point72 Middle East FZE sold out of 4D Molecular Therapeutics (FDMT) in Q4 2023, closing a stake of 11,304 shares — an estimated $144K sold.

Point72 Middle East FZE first reported a position in FDMT in Q3 2023 and held it in 1 quarter. The position peaked at $144K in Q3 2023. 111 funds tracked by Wall St. Rank hold FDMT as of Q4 2023.

  • Point72 Middle East FZE reported no remaining 4D Molecular Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 11,304 4D Molecular Therapeutics shares in Q4 2023, an estimated $144K.
  • Point72 Middle East FZE first reported a position in 4D Molecular Therapeutics in Q3 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's 4D Molecular Therapeutics position peaked at $144K in Q3 2023.
  • 111 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.